Your browser doesn't support javascript.
loading
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
Pizzamiglio, Sara; Cosentino, Giulia; Ciniselli, Chiara M; De Cecco, Loris; Cataldo, Alessandra; Plantamura, Ilaria; Triulzi, Tiziana; El-Abed, Sarra; Wang, Yingbo; Bajji, Mohammed; Nuciforo, Paolo; Huober, Jens; Ellard, Susan L; Rimm, David L; Gombos, Andrea; Daidone, Maria Grazia; Verderio, Paolo; Tagliabue, Elda; Di Cosimo, Serena; Iorio, Marilena V.
Afiliação
  • Pizzamiglio S; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Cosentino G; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Ciniselli CM; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • De Cecco L; Integrated Biology Platform, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Cataldo A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Plantamura I; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Triulzi T; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • El-Abed S; Breast International Group (BIG), Brussels, Belgium.
  • Wang Y; Novartis Pharma AG, Basel, Switzerland.
  • Bajji M; Institute Jules Bordet (IJB), Brussels, Belgium.
  • Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Huober J; Breast Center, Cantonal Hospital, St. Gallen, Switzerland.
  • Ellard SL; BC Cancer, Kelowna, British Columbia, Canada.
  • Rimm DL; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Gombos A; Institute Jules Bordet (IJB), Brussels, Belgium.
  • Daidone MG; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Verderio P; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Di Cosimo S; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Iorio MV; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Cancer Med ; 11(2): 332-339, 2022 01.
Article em En | MEDLINE | ID: mdl-34921525
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Receptor ErbB-2 / MicroRNAs Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Cancer Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Receptor ErbB-2 / MicroRNAs Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Cancer Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália